A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.
Inclusion Criteria:
Exclusion Criteria:
Fayetteville, Arizona, United States
Hot Springs, Arizona, United States
Tulsa, Arizona, United States
Raleigh, California, United States
New Port Richie, Florida, United States
Saint Peters, Mississippi, United States
Canberra, New South Wales, Australia
Manuels, Newfoundland and Labrador, Canada
Ste-Foy, Quebec, Canada
Rio Pieoras, Puerto Rico